Table 2.
Univariable and multivariable analyses of local recurrence
| Covariates | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | CI | p-value | HR | CI | p-value | |
| Dose group | ||||||
| High-dose (reference) | 1.00 | – | – | 1.00 | – | – |
| Standard-dose | 3.08 | 1.30–7.34 | 0.011 | 4.09 | 1.65–10.14 | 0.002 |
| Age (years) | ||||||
| 40–64 (reference) | 1.00 | – | – | – | – | – |
| 65–74 | 0.94 | 0.39–2.26 | 0.88 | – | – | – |
| 75–86 | 0.87 | 0.32–2.36 | 0.79 | – | – | – |
| Sex | ||||||
| Female (reference) | 1.00 | – | – | – | – | – |
| Male | 0.96 | 0.33–2.77 | 0.93 | – | – | – |
| Tumor location | ||||||
| Mt (reference) | 1.00 | – | – | 1.00 | – | – |
| Ce or Ut | 2.34 | 0.87–6.29 | 0.092 | 3.39 | 1.17–9.78 | 0.024 |
| Lt | 1.89 | 0.77–4.66 | 0.16 | 3.00 | 1.13–7.93 | 0.027 |
| Tumor length (mm) | ||||||
| ≤ 40 (reference) | 1.00 | – | – | 1.00 | – | – |
| > 40 and ≤ 80 | 0.33 | 0.11–0.99 | 0.048 | 0.42 | 0.14–1.28 | 0.13 |
| > 80 | 1.18 | 0.46–3.02 | 0.73 | 2.72 | 0.90–8.21 | 0.075 |
| Clinical depth of invasion | ||||||
| EP/LPM or MM/SM1 (reference) | 1.00 | – | – | 1.00 | – | – |
| SM2 | 2.37 | 1.03–5.46 | 0.042 | 2.89 | 1.14–7.34 | 0.026 |
| Chemotherapy | ||||||
| Cisplatin + 5-fluorouracil (reference) | 1.00 | – | – | – | – | – |
| Others | 1.83 | 0.55–6.08 | 0.33 | – | – | – |
Abbreviations: HR Hazard ratio, CI Confidence interval, Mt Middle thoracic esophagus, Ce Cervical esophagus, Ut Upper thoracic esophagus, Lt Lower thoracic esophagus, EP/LPM Tumor limited to the epithelium or invading the lamina propria mucosa, MM/SM1 Tumor invading the muscularis mucosa or submucosa to a depth of ≤ 200 μm from the lower border of the muscularis mucosa, SM2 Tumor invading the submucosa to a depth of > 200 μm